Cantor Fitzgerald analyst Steve Seedhouse last night initiated coverage of Astria Therapeutics (ATXS) with an Overweight rating and $47 price target The firm expects the company’s lead YTE-modified anti-kallikrein antibody navenibart to be more efficacious than any other therapeutic approved or in development for hereditary angioedema. The three month dose is a meaningful difference in convenience versus other therapies, the analyst tells investors in a research note. Cantor adds that HAE patients have shown propensity to start or switch to therapies that are more convenient.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Astria Therapeutics price target raised to $28 from $27 at Wedbush
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating